Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment
- Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection
- Trial targeted to begin in 1Q2021 at multiple sites across the UK